Finding value in the pharmaceutical sector

  • Most drug stocks have been out of favor in 2023
  • Pharma companies are facing challenges such as Medicare drug-price negotiation program and patent expirations
  • There might be value hiding in the sector
  • Five drug stocks with room to grow: Pfizer, Viatris, Bristol Myers Squibb, Zoetis, and AstraZeneca
  • Pfizer tops the list with potential upside of 37%
  • Viatris has a potential upside of 31.2%
  • AstraZeneca is a Wall Street analyst darling

Public Companies: Pfizer (PFE), Johnson & Johnson (JNJ), Eli Lilly (LLY), Bristol Myers Squibb (BMY), Viatris (VTRS), Zoetis (ZTS), AstraZeneca (AZN), Novo Nordisk (NVO)
Private Companies:
Key People: Amir Hamja (Scientist), Jason Gerberry (Analyst)

Track all markets on TradingView

Factuality Level: 7
Justification: The article provides information about the performance of drug stocks in 2023 and the reasons for the selloff. It also mentions the potential value in the sector and lists five drug stocks with room to grow. The information is based on market data and analyst target prices. However, the article does not provide a balanced view as it only focuses on the potential upside of the selected stocks and does not mention any potential risks or downsides.

Noise Level: 3
Justification: The article provides information on the performance of pharmaceutical stocks and the reasons behind the selloff. It also highlights potential value in the sector and identifies five stocks with room to grow. The article includes average target prices and potential upside for each stock. However, it lacks in-depth analysis and does not provide evidence or data to support its claims.

Financial Relevance: Yes
Financial Markets Impacted: Pharmaceutical companies such as Pfizer, Johnson & Johnson, Eli Lilly, Bristol Myers Squibb, Zoetis, and AstraZeneca

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article discusses the performance of drug stocks in the market and the factors that have contributed to their decline. It also highlights potential value in the sector and identifies specific pharmaceutical companies with room for growth. However, there is no mention of any extreme events or their impact.

Reported publicly: www.marketwatch.com